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Statin use and cardiovascular risk 
factors in diabetic patients developing a first 
myocardial infarction
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Abstract 
Background: The risk for a first myocardial infarction (MI) in people with diabetes has been shown to be as high as 
the risk for a new MI in non-diabetic patients with a prior MI. Consequently, risk-reducing statin therapy is recom-
mended for nearly all patients with diabetes 40 years of age or older, regardless of cholesterol level. The purpose of 
this study was to assess the recommended and real-life use of statins for primary prevention of atherosclerotic cardio-
vascular disease (ASCVD) in diabetic patients who develop ASCVD.
Methods: In a cross-sectional multicenter study of consecutive patients without previous ASCVD hospitalized with a 
first MI in 2010–2012, we obtained information on diabetic status, statin use, and cardiovascular risk factors prior to MI.
Results: The study population consisted of 1622 patients with first MI (63 % men), 228 of whom had known dia-
betes before MI. All but three of the diabetic patients were ≥40 years of age. Diabetic patients were older (70 vs 68, 
p = 0.006), were more often women (43 vs 36 %, p = 0.05) and had a higher prevalence of statin use (47 vs 11 %, 
p < 0.001) compared with non-diabetic patients. Despite a high risk factor burden, the majority (53 %) of patients with 
known diabetes was not treated with statins before MI, and there was no relationship between the number of high-
risk markers and statin use. Nearly all diabetic patients not treated with statins before first MI had at least one marker 
of very high cardiovascular risk, including hypertension (71 %), current smoking (37 %), and nephropathy (33 %).
Conclusions: Primary prevention with statins had been initiated in less than half of diabetic patients destined for a 
first MI, despite the presence of one or more markers of very high cardiovascular risk in nearly all. These results high-
light an urgent need for optimizing statin therapy and global risk factor control in diabetic patients.
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Background
It has been known for decades that diabetes is a power-
ful risk factor for atherosclerotic cardiovascular disease 
(ASCVD) [1]. Nevertheless, it came as a surprise when a 
study published in 1998 indicated that the risk for a first 
myocardial infarction (MI) in people with type 2 diabe-
tes was as high as the risk for a new MI in non-diabetic 
patients with prior MI [2]. Consequently, the American 
NCEP (National Cholesterol Education Program) clinical 
guidelines defined diabetes as a coronary heart disease 
(CHD) risk equivalent with similar intensity and goal of 
cholesterol-lowering therapy as in patients with known 
CHD [3]. Similarly, in 2003, the European guidelines on 
ASCVD prevention defined diabetes type 2 and diabe-
tes type 1 with microalbuminuria as high-risk conditions 
and recommended similar treatment goals for diabetic 
patients without ASCVD and nondiabetic patients with 
established ASCVD [4]. Today, risk-reducing statin ther-
apy is recommended for nearly all patients with diabetes 
40  years of age or older, regardless of cholesterol level 
[5–11].
To what extent this recommendation is followed in 
routine clinical practice is not known. Therefore, to 
address this question, we assessed the uptake of primary 
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prevention with statins in contemporary and consecutive 
diabetic patients hospitalized with MI as first manifesta-
tion of ASCVD.
Methods
We identified consecutive patients with a first MI without 
prior ASCVD (hereafter just called first MI) admitted to 
four hospitals in Denmark in 2010 through 2012 (Aarhus 
University Hospital and the Regional Hospitals in Rand-
ers, Herning and Horsens). From the medical records 
we collected information about known diabetes treated 
with diet or drugs (~9  % were type 1 diabetes), use of 
statins and anti-hypertensive agents, and cardiovascu-
lar risk factor burden before hospitalization for first MI. 
The universal definition of MI is implemented in Den-
mark, requiring clinical evidence of myocardial ischemia 
together with elevated biomarkers reflecting myocardial 
necrosis [12]. The traditional cardiovascular risk factors 
[age, sex, smoking status, total cholesterol, low-density 
lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), and systolic blood pressure] were 
assessed as previously described [13]. Plasma lipid values 
were obtained within 24 h after admission and/or avail-
able from a prior contact with the health care system. 
The blood pressure used for risk estimation was obtained 
prior to admission (if hospitalized previous year) or 
after recovery from MI (before hospital discharge or at 
first visit to the rehabilitation clinic). Hypertension was 
defined as SBP >140 mmHg and/or use of anti-hyperten-
sive agents at admission.
Risk assessment
In 2003, the European Society of Cardiology (ESC) guide-
lines on ASCVD prevention introduced a new multi-
factorial risk assessment model for use in the primary 
prevention of ASCVD in people 40–65  years of age 
without diabetes, SCORE (Systematic Coronary Risk 
Evaluation) [4]. Patients with diabetes were classified as 
high-risk, regardless of other cardiovascular risk factors, 
and treatment decisions should in principle not be based 
on SCORE. However, it was suggested that SCORE could 
be used for a rough assessment of cardiovascular risk in 
diabetic patients, recognizing that the real risk would be 
at least twice as high in diabetic men and up to four times 
higher in diabetic women as that given by SCORE [14]. 
A more recent re-analysis of the SCORE database indi-
cated that the impact of diabetes on risk might be even 
greater, with relative risks of ~5 in women and ~3 in 
men [5, 6, 15]. With this in mind, we calculated SCORE 
in the total population and estimated also the real risk in 
patients with diabetes by multiplying the SCORE risk by 
5 in women and 3 in men.
The SCORE predictors used to calculate the 10-year 
risk for fatal CVD include sex, age, smoking status, total 
cholesterol and systolic blood pressure [4–6]. We used the 
published SCORE equations [14] to calculate the 10-year 
risk and capped the age-related risk at age 65 in agreement 
with the assumptions and complying with clinical practice 
[4–6]. SCORE was created for use in non-diabetic people 
40–65 years of age [14], risk charts are available only for 
people in this age range [4–6], and the age-related risk is 
capped at age 65 in the online risk calculator, HeartScore 
[16]. We used the low-risk SCORE equations, as recom-
mended for Denmark in the most recent ESC guideline 
[6]. In patients without diabetes, statin therapy is indi-
cated or should be considered if SCORE is ≥5 %, defined 
as high (5–10 %) or very-high (≥10 %) risk [6].
Primary prevention with statins in diabetes
In diabetic patients, primary prevention with statins 
is recommended or should be considered in nearly all 
≥40 years of age, with the intensity of therapy depending 
on the presence of other cardiovascular risk factors and 
end-organ damage [5–7]. Diabetes (type 1 or type 2) with 
≥1 cardiovascular risk factor and/or end-organ damage 
is classified as very high risk, corresponding to SCORE 
≥10 % and with a class I recommendation for statin ther-
apy similar to patients with documented ASCVD [5–7]. 
The national Danish guidelines follow these European 
guidelines [17–22].
The study was approved by the Danish Data Protection 
Agency (Reference: 2007-58-0010, int. ref: 1-16-02-46-
12). Registry studies do not require ethical approval in 
Denmark.
Statistical analysis
Statistical analysis was performed using Stata version 
13.1 SE (StataCorp LP, College Station, TX, USA). Base-
line characteristics were compared with Student’s t test, 
Mann–Whitney test or Fisher’s exact test (categorical 
variables). The 10-year risk of fatal CVD was calculated 
for each patient using the low-risk SCORE algorithms 
[14]. We used logistic regression analyses to assess the 
association between risk factors and use of statins in dia-
betic patients before MI. These results are presented as 
odds ratio (OR) with 95 % confidence intervals (CI).
Results
Among 1632 consecutive patients with first MI, informa-
tion about diabetes and/or statin use before MI was avail-
able in all but ten patients (study population, Table  1). 
The majority (63  %) were men. They were ~7  years 
younger than women and had a higher predicted risk 
estimated by SCORE (mean 4.6 vs. 2.8 %).
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Prevalence of diabetes in patients with first MI
The prevalence of known diabetes among patients with 
first MI was 14 % (Table 1), and this prevalence was con-
sistent across different age groups (Fig. 1). All but three 
of the 228 patients with known diabetes before MI were 
≥40 years of age.
Diabetic patients were older (70 vs 68, p  =  0.006), 
were more often women (43 vs 36 %, p = 0.05) and had a 
higher prevalence of hypertension (79 vs 63 %, p < 0.001) 
compared to non-diabetic patients with first MI (Table 2), 
while the prevalence of smoking was equally high (36 vs 
39  %, p  =  0.34). In contrast, total and LDL cholesterol 
levels were significantly lower among diabetic patients 
explained, at least partly, by their higher prevalence 
of statin use prior to MI. Similar results were observed 
when stratified by gender (Table 3).
Statin vs. non‑statin use in diabetic patients
The majority (53  %) of diabetic patients was not using 
statins before their first MI (Table 4). Many of those not 
treated with statins before MI had hypertension (71  %) 
or were current smokers (37 %). Nearly all (~95 %) had 
at least one and the majority had two or more of the fol-
lowing markers of very high cardiovascular risk: hyper-
tension, smoking, family history of CHD or nephropathy 
(GFR < 60 mL/min/1.73 m2) (Fig. 2).
In patients using statins before MI we added 
1.5 mmol/L to the measured on-treatment total choles-
terol concentration [23] and then calculated the SCORE 
risk, using this as an estimate for the pre-treatment 
SCORE risk. To get an estimate of the real risk by tak-
ing the diabetes-related risk into account, we multi-
plied the calculated SCORE risk by 3 in men and 5 in 
women [5, 6, 15]. The average 10-year risk for fatal CVD 
was >10  % (very high risk) not only in those on statins 
Table 1 Study population: patients with  first myocardial 
infarction without prior atherosclerotic cardiovascular dis-
ease
Baseline characteristics are provided as mean (standard deviation) for 
continuous values
a SCORE was calculated by the low-risk equations published by Conroy et al. 
[14]. The on-treatment cholesterol concentration was used for calculation of 







Gender, % – 63 37
Age, year 68.0 (14.1) 65.4 (13.2) 72.3 (14.4)
Smoking, % 38 42 32
Total cholesterol, mmol/L 5.1 (1.2) 5.0 (1.1) 5.3 (1.4)
LDL cholesterol, mmol/L 3.2 (1.1) 3.2 (1.0) 3.2 (1.2)
HDL cholesterol, mmol/L 1.3 (0.4) 1.2 (0.4) 1.5 (0.5)
Triglycerides, mmol/L 1.6 (1.2) 1.6 (1.3) 1.5 (1.0)
Systolic blood pressure, mmHg 138 (20.5) 138 (19.9) 138 (21.5)
Hypertension, % 65 61 72
Statin, % 16 15 18
Diabetes, % 14 13 16
SCORE (mean)a, % 3.9 (3.2) 4.6 (3.4) 2.8 (2.1)
Fig. 1 Prevalence of diabetes among patients with first myocardial 
infarction. The prevalence of known diabetes was similar in all age 
groups
Table 2 Study population stratified by  known diabetes 
prior to first myocardial infarction
Baseline characteristics are provided as mean (standard deviation) for 
continuous values
a SCORE was calculated by the low-risk equations published by Conroy et al. 
[14]. The on-treatment cholesterol concentration was used for calculation of 
SCORE in those treated with statins. SCORE was not created for use in patients 
with diabetes who are classified as high or very high risk, regardless of SCORE
Diabetes No diabetes p value
n = 228 n = 1394
Gender (male), % 57 64 0.05
Age, year 70.3 (13.8) 67.6 (14.1) 0.006
Smoking, % 36 39 0.34
Total cholesterol, mmol/L 4.5 (1.4) 5.2 (1.2) <0.001
LDL cholesterol, mmol/L 2.5 (1.1) 3.3 (1.1) <0.001
HDL cholesterol, mmol/L 1.2 (0.4) 1.3 (0.4) <0.001
Triglycerides, mmol/L 1.9 (1.4) 1.5 (1.1) <0.001
Systolic blood pressure, mmHg 138 (23) 138 (20) 0.68
Hypertension, % 79 63 <0.001
Statin, % 47 11 <0.001
SCORE (mean)a,  % 3.8 (2.9) 4.0 (3.2) 0.4
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before MI (pre-treatment risk) but also in those not 
on statins (Table  4). A similar proportion of diabetic 
patients treated or not treated with statins before MI had 
a real cardiovascular risk higher than the 5  % high-risk 
threshold defined by the ESC guidelines (91 % vs. 85 %, 
p = 0.22; Table 4) [4–6]. The 10-year risk for fatal CVD 
would have been even higher if we instead of the low-
risk SCORE equations had used the high-risk equations 
to estimate risk, which were recommended in Denmark 
during the study period [15].
Factors associated with statin use in diabetic patients
The multivariable adjusted association of cardiovascular 
risk factors with statin use in diabetic patients is shown 
in Table 5. Total cholesterol and hypertension were asso-
ciated with taking statins prior to MI, while age, gender 
and smoking status were not. These results were similar 
in men and women separately. Surprisingly, increasing 
number of high-risk markers (hypertension, smoking, 
family history of CHD and nephropathy) was not signifi-
cantly associated with statin treatment prior to MI (odds 
ratio of 1.11 (0.81–1.54, p = 0.49) per high-risk marker) 
(Fig. 2).
Discussion
Among consecutive patients with MI as first manifesta-
tion of ASCVD, 14 % had known diabetes before MI. Pri-
mary prevention with statins had been initiated in 47 and 
11  % of those with or without known diabetes, respec-
tively. Nearly all diabetic patients not treated with statins 
before first MI had at least one marker of very high car-
diovascular risk, including hypertension (71  %), smok-
ing (37  %) and nephropathy (33  %). Surprisingly, these 
markers of very high cardiovascular risk were not more 
prevalent in diabetic patients treated with statins prior 
to MI compared with diabetic patients not treated with 
statins.
Known diabetes before first MI
With the growing burden of obesity and type 2 diabe-
tes, it may appear surprising that only 14  % of first MI 
occurred in patients with known diabetes. However, this 
is in line with 11  % in the Danish DANAMI-2 study in 
patients with ST-elevation MI [24] and 15  % in a more 
recent Swiss study in patients with first acute coronary 
syndrome [25]. In the INTERHEART study, the preva-
lence of diabetes was 18 % in patients with first MI [26]. 
A much higher prevalence of diabetes among MI patients 
have been reported in studies that included patients with 
both first and recurrent MI and diabetes diagnosed not 
only before but also after admission [27–29].
Diabetes‑related risk
In the decades-old SCORE cohorts, information on dia-
betes was not collected uniformly to allow inclusion of 
diabetes as a predictor in the SCORE model [14]. Instead 
diabetes type 2 (and type 1 with microalbuminuria) was 
defined as a high-risk condition with similar targets for 
cholesterol-lowering treatment as in patients with clini-
cally established ASCVD [4]. In the most recent ESC 
guidelines, patients with diabetes were classified as high 
(SCORE 5–10  %) or very-high (SCORE ≥10  %) risk 
depending on the presence of cardiovascular risk fac-
tors and end-organ damage [6]. It was stated that a re-
analysis of the SCORE database indicated that diabetes 
increases the risk for fatal ASCVD ~5 times in women 
Table 3 Study population stratified by known diabetes and gender prior to first myocardial infarction
Baseline characteristics are provided as mean (standard deviation) for continues values
a SCORE was calculated by the low-risk equations published by Conroy et al. [14]. The on-treatment cholesterol concentration was used for calculation of SCORE in 











Age, year 68.4 (13.7) 65.0 (13.1) 0.006 72.9 (13.5) 72.2 (14.6) 0.64
Smoking,  % 36 43 0.12 35 32 0.49
Total cholesterol, mmol/L 4.3 (1.3) 5.1 (1.1) <0.001 4.7 (1.4) 5.4 (1.3) <0.001
LDL cholesterol, mmol/L 2.5 (1.1) 3.3 (1.0) <0.001 2.6 (1.2) 3.3 (1.2) <0.001
HDL cholesterol, mmol/L 1.2 (0.4) 1.2 (0.4) 0.17 1.3 (0.4) 1.5 (0.5) <0.001
Triglycerides, mmol/L 1.8 (1.2) 1.6 (1.3) 0.07 2.0 (1.7) 1.4 (0.8) <0.001
Systolic blood pressure, mmHg 139 (20.8) 138 (19.7) 0.39 138 (24.9) 138 (20.8) 0.73
Hypertension, % 78 59 <0.001 82 70 0.02
Statin, % 45 10 <0.001 49 12 <0.001
SCORE (mean)a, % 4.4 (3.2) 4.6 (3.5) 0.59 2.8 (2.2) 2.8 (2.1) 0.73
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and ~3 times in men [5, 6, 15]. Based on this information 
we estimates a likely risk in the diabetic patients with first 
MI and found that most passed the 10 % very high risk 
threshold set by the ESC guidelines, and nearly all passed 
the 5 % high risk threshold (Table 4). However, consider-
ing the substantial decline in ASCVD mortality since the 
SCORE data was collected decades ago, the relevance of 
these estimates may be questioned.
More recent data indicates that the diabetes-related 
risk is heterogeneous and often lower than that esti-
mated from the SCORE database, depending on the used 
predictors, predicted outcomes (e.g., fatal vs. non-fatal 
ASCVD), presence of other cardiovascular risk factors 
and end-organ damage, and duration of diabetes [30, 31]. 
Worth to recognize is that a study that contributed sig-
nificantly to the classification of diabetes as a CHD risk 
equivalent originated from a high-risk country (Finland 
in the 1980s), with a high prevalence of hypercholester-
olemia and hypertension in the diabetic population, and 
an average duration of diabetes of 8  years [2, 3]. Today, 
screen-detected and treated diabetes is associated with 
a much lower cardiovascular risk [32], but still with a 
Table 4 Diabetic patients stratified by  statin use prior 
to first myocardial infarction
Baseline characteristics are provided as mean (standard deviation) for 
continuous values
a SCORE was calculated after adding 1.5 mmol/L to the measured on-treatment 
total cholesterol concentration (an estimate of the pre-treatment SCORE risk)
b SCORE risk multiplied by 3 in men and 5 in women to take the diabetes-
related risk into account [5, 6, 15]
c GFR glomerular filtration rate; GFR < 60 mL/min/1.73 m2 is defined as 







Gender, % – – 0.51
Age, year 70.1 (12.0) 70.6 (15.2) 0.80
Smoking, % 34 37 0.21
Total cholesterol, mmol/L 4.1 (1.2) 4.8 (1.4) <0.001
LDL cholesterol, mmol/L 2.1 (0.9) 2.9 (1.2) <0.001
HDL cholesterol, mmol/L 1.2 (0.4) 1.2 (0.4) 0.42
Triglycerides, mmol/L 1.8 (1.6) 1.9 (1.3) 0.45
Systolic blood pressure, 
mmHg
139 (21.5) 138 (24.0) 0.76




GFRc, mL/min/1.73 m2 64 (27.3) 72 (27.3) 0.03
Nephropathy (GFR < 60)c,  % 43 33 0.69
Family history of CHD,  % 37 34 0.62
LDL cholesterol 
≥2 mmol/L,  %
54 81 <0.001
LDL cholesterol 
≥1.8 mmol/L,  %
57 83 <0.001
SCORE (mean),  % – 3.8 (2.8)
SCORE (mean) before statin 
therapya, %
4.6 (3.8) –
Estimated 10-year risk in 
diabetes (mean)b,  %
16.6 (12.4) 13.7 (10.2) 0.10
Estimated 10-year risk in 
diabetes ≥5 %b, n/n
91 % 85 % 0.22
Fig. 2 Markers of high cardiovascular risk in diabetic patients with 
first myocardial infarction, stratified by statin use. The high-risk mark-
ers were smoking, hypertension, family history of coronary heart 
disease, and nephropathy. There was no significant relationship 
between the number of markers of high or very high risk and statin 
use prior to a first myocardial infarction [odds ratio of 1.11 (0.81–1.54, 
p = 0.49) per high-risk marker]. Regardless of statin use, nearly all 
diabetic patients had at least 1 high-risk marker and the majority had 
2 or more high-risk markers prior to myocardial infarction. Analyses 
were performed among the 177 diabetic patients in whom we had 
complete information on all markers of high risk, including family 
history of coronary heart disease
Table 5 Association between  cardiovascular risk factors 
and statin use in diabetic patients prior to first myocardial 
infarction
Multivariable adjusted odds ratios with 95 % confidence intervals (CI) calculated 
using logistic regression
a 1.5 mmol/L were added to the measured on-treatment total cholesterol 
concentration in patients taking statins before myocardial infarction
Risk factor Odds ratio (95 % CI) for statin use
Overall Men Women
Age, per 5-year 
increase
0.97 (0.87–1.09) 1.07 (0.93–1.24) 0.82 (0.68–0.99)
Sex 1.0 (0.55–1.81) – –
Current smoking 0.77 (0.41–1.45) 0.83 (0.36–1.95) 0.68 (0.25–1.82)
Total cholesterola 1.51 (1.22–1.87) 1.66 (1.24–2.22) 1.29 (0.93–1.79)
Hypertension 3.36 (1.53–7.35) 3.06 (1.14–8.27) 5.46 (1.35–22.08)
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stronger impact of diabetes on ASCVD risk in women 
than men. Why remains unclear [33].
Much remains to be understood about the diabetes-
related risk for ASCVD. It is still uncertain whether 
hyperglycemia per se accelerates the development of 
atherothrombosis, and if it does, whether qualitative 
(plaque vulnerability) or quantitative (plaque burden) 
changes are most important [34]. Targeting the tradi-
tional cardiovascular risk factors such as high blood pres-
sure and cholesterol is at least as important in patients 
with diabetes as in those without diabetes [35]. Interest-
ingly, statin therapy before a first MI may improve long-
term survival in overweight patients with diabetes [36]. 
Even though concerns have been raised about the dia-
betogenic effect of statin therapy [37], statins certainly 
reduce the risk for ASCVD in patients with diabetes.
Primary prevention with statins in diabetes
Based on evidence from randomized controlled trials 
[38–40], current guidelines recommend primary pre-
vention with statins to nearly all adults with diabetes 
[5–11, 17–22]. The strong indication for statin therapy 
to patients with diabetes, especially in the presence of ≥1 
cardiovascular risk factor and/or end-organ damage, is 
not new and was effective during the present study period 
[17, 18]. The European (and Danish) guidelines recom-
mend therapeutic goals, but we focused primarily on 
initiation of statin therapy rather than on treatment goal 
because it is more important to initiate therapy than to 
intensify it to fulfil a treat-to-target strategy [41]. There-
fore, it came as a surprise that statin therapy had been 
initiated in less than half of patients with known diabe-
tes before first MI, in particular because nearly all had at 
least one easily identifiable marker of very high risk, such 
as hypertension, smoking, family history of CHD, and/or 
nephropathy. Thus, the current practice of selective use 
of statins for the primary prevention of ASCVD in some 
but not other patients with diabetes does not seem to tar-
get treatment to those at highest risk. The same appears 
to be the case in non-diabetic patients destined for a first 
MI [42].
Our data do not explain why so many diabetic patients 
at very high cardiovascular risk are not treated with 
statins. Denmark has a universal healthcare system that 
covers all citizens. Visits to general practitioners and 
specialists are free of charge, and diabetic patients are 
followed regularly by their general practitioner and/
or diabetes outpatient clinics. The European guidelines 
on ASCVD prevention classified diabetes as a high-risk 
condition more than 10  years ago [4]. These guidelines 
were endorsed by Danish medical societies including, 
among others, the Danish Society of Cardiology, Danish 
Endocrine Society, and the Danish College of General 
Practitioners, and the importance of primary preven-
tion with statins to diabetic patients at high risk has been 
stressed for many years [17–22]. However, the adherence 
to guideline recommendations is often low in general 
practice [43]. In a recent primary care study, only 45  % 
of patients with known type 2 diabetes were treated with 
a statin or another lipid-lowering drug [43]. The propor-
tion of patients with screen-detected diabetes treated 
with statins varied widely between general practices, 
from 0 to 100 % [44]. In the ADDITION trial, in which 
general practitioners voluntarily had agreed to compare 
routine care of screen-detected diabetes with intensive 
treatment of multiple risk factors, the adherence to the 
given recommendations was low [44], which might have 
contributed to the neutral results [32]. Although patients 
differ in their willingness and ability to comply with pre-
scribed medication, the great variability among general 
practitioners in the use of statins in patients diagnosed 
with diabetes indicates that primary care providers play a 
critical role in optimal implementation of the guidelines.
Smoking in diabetes
Active smoking increases the risk of type 2 diabetes, 
amplifies the diabetes-related risk for ASCVD, and accel-
erates the progression of diabetic nephropathy [45–47]. 
In Denmark, 10–15  % of the general population were 
current smokers in 2010–2012 [48]. In the present study, 
more than one-third of both the diabetic (36 %) and the 
non-diabetic (39  %) patients with first MI were current 
smokers, confirming the strong impact of smoking on 
cardiovascular risk. The recommendation to stop smok-
ing is unanimously strong [7, 11, 17–19] even though the 
glycemic control may deteriorate temporarily after cessa-
tion of smoking [49]. The high prevalence of smoking in 
diabetic patients at very high risk for ASCVD indicates 
that current guidelines are insufficiently implemented.
Strengths and limitations
Our study has several important strengths. The study 
population consists of contemporary and consecutive 
(unselected) real-world patients with a first MI (hard 
ASCVD endpoint). Thus, the age, sex and risk factor dis-
tribution is representative of that seen in daily clinical 
practice of patients with first MI. Statin use before MI 
was assessed in patients who knew they had diabetes and 
were treated with diet and/or anti-diabetic drugs before 
the acute event.
A limitation is the retrospective nature of the study. 
Potential limitations of risk factor assessment after ver-
sus before MI is not pertinent to the key message of the 
present study and has been discussed previously [13]. We 
may have underestimated the cardiovascular risk prior 
to statin therapy just by adding 1.5 mmol/L to the total 
Page 7 of 8Mortensen et al. Cardiovasc Diabetol  (2016) 15:81 
cholesterol concentration, because people who decide 
to take statins may also try to improve other risk factors 
than cholesterol.
Conclusion
Approximately 14 % of 1622 consecutive patients hospi-
talized with a first MI had known diabetes. Primary pre-
vention with statins had been initiated in less than half of 
the diabetic patients, although nearly all had one or more 
markers of very high cardiovascular risk. These results 
highlight an urgent need for optimizing statin therapy 
and global risk factor control in diabetic patients without 
known ASCVD.
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